| Acquirer | Target | Price |
|---|---|---|
| OptumRx | AlexaCare Holdings, Inc. | N/A |
| Charles River Laboratories | Oncotest GmbH | $36 million |
| CONMED Corporation | SuriQuest, Inc. | $265 million |
| ams AG | CMOSIS | $235 million |
| Depomed Inc. | Depomed Inc. Rights to cebranopadol | N/A |
Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
